Immunitybio Inc (IBRX)

$7.30 +0.16 (2.24%)
Market Cap 7.51B
Revenue (ttm) 113.29M
Net Income (ttm) -351.40M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -310.18%
Debt to Equity Ratio 0.00
Volume 14,223,000
Avg Vol 34,007,184
Day's Range N/A - N/A
Shares Out 1.03B
Stochastic %K 25%
Beta 0.13
Analysts Strong Sell
Price Target $14.80

Company Profile

ImmunityBio, Inc., a biotechnology company, focuses on innovating, developing, and commercializing next-generation immunotherapies designed to activate the patient's immune system and deliver durable protection against cancer and infectious diseases. Its platforms for the development of biologic products and product candidates that include cytokine fusion proteins, DNA and vaccine vectors, and cell therapies. The company's platform has generated first-in-human therapeutic agents that are planned...

Industry: Biotechnology
Sector: Healthcare
Phone: 844 696 5235
Address:
3530 John Hopkins Court, San Diego, United States
LB19
LB19 Apr. 4 at 1:33 PM
$IBRX look at this, look. King Faisal hospital in Saudi, our partnership with them. Sepsis and pneumonia... BioShield etc!
1 · Reply
BeMarsh
BeMarsh Apr. 4 at 1:30 PM
$IBRX
0 · Reply
JayMacy
JayMacy Apr. 4 at 1:27 PM
$IBRX Why did he have to turn his head?
1 · Reply
Rambo309
Rambo309 Apr. 4 at 1:00 PM
$IBRX Hey guys imo this war will not end that soon, bc the more shit happens, the later it will end. I think this coming week will be another test for us shareholder. As long as this war goes on realistically we will have more downs than ups, so we have to stay strong! Just curious when do u guys think this war might end?
2 · Reply
CyberCuba
CyberCuba Apr. 4 at 12:57 PM
$IBRX I agree with thelibsrdum LUKE P HUDOCK post a few minutes ago. Specifically with Type A influenza pneumonia in which severe lymphocytopenia is associated with increased mortality and superinfections such as Aspergillus. Aggressively treating sepsis and influenza patients who are lymphocytopenic is a potential huge market for IBRX Anktiva.
0 · Reply
LB19
LB19 Apr. 4 at 12:54 PM
$IBRX right after posting job for Field Reimbursement Manager who will be responsible for services pertaining to access, coverage, coding, reimbursement, and affordability of IBRX therapeutic products. Then Patrick started all this talk in regards to pneumonia and Sepsis. This also comes after Patrick pounding the table on "Plausible mechanism of action"! It's all being laid out there for us to see, the foundation is being set. All the Dunkirk activity and job postings is not for manufacturing just for the very limited approvals we have. They know what is coming.
0 · Reply
thelibsrdum
thelibsrdum Apr. 4 at 12:34 PM
$IBRX if CAP/sepsis proves to be a successful indication for Anktiva, this is bigger than cancer. This would be a frontline treatment for every pneumonia patient with lightning fast adoption and is in an area BP doesn't even play so all those headwinds disappear. As much as everyone is focused on cancer, this alternative indication could be the moonshot while cancer indication moves along at a much slower
0 · Reply
Regener8
Regener8 Apr. 4 at 11:54 AM
$IBRX $IBRX I wasn’t aware of the Phase 3 registration! (See below) The specific pairing for severe CAP (targeting sepsis-related immunoparalysis/lymphopenia) does not show a preceding standalone Phase 1 in public records or company announcements. The jump to Phase 2 is common when leveraging established safety profiles from related indications, especially for a serious, high-unmet-need condition like severe pneumonia in ICU patients. A separate Phase 3 randomized, blinded, placebo-controlled trial (NCT07492875) for the same combination in severe CAP has also been registered, indicating the program is moving quickly from the small Phase 2 toward confirmatory testing.  This approach aligns with ImmunityBio’s focus on restoring immune competence in lymphopenic or immunosuppressed states, building on data from their cancer and long COVID trials where ANKTIVA has shown lymphocyte-boosting effects. This has the chance to be much bigger than just treating cancer and they are on it! Go Doc!
1 · Reply
NasdaqPulse
NasdaqPulse Apr. 4 at 11:45 AM
The best opportunities don’t show up when everyone agrees — they show up when sentiment is at its worst and volatility is at its highest. 👉Click to view @NasdaqPulse for timely updates amid the volatility. High-beta names are getting punished, but that’s exactly where asymmetric upside lives. Watch these levels, not headlines: • $IBRX • $ACHR • $ORCL • $QBTS • $CRWV The strategy isn’t to chase — it’s to accumulate when weakness persists and liquidity thins out. Volatility = opportunity Fear = entry signal (not exit signal) Patience is the edge here. A bit more downside… and risk/reward starts to skew heavily in your favor. That’s when capital should be deployed — not after the move.
0 · Reply
Mayor_Shark
Mayor_Shark Apr. 4 at 11:34 AM
$IBRX Always so odd to see how hateful bears can be on drugs that are being made to save lives. This Easter I pray for you to have hearts ✝️✌️
0 · Reply
Latest News on IBRX
ImmunityBio (IBRX) Sued After FDA Flags Misleading Cancer Claims, Shares Plunge 21%, $2B Market Cap Lost -- Hagens Berman

Apr 1, 2026, 4:07 PM EDT - 2 days ago

ImmunityBio (IBRX) Sued After FDA Flags Misleading Cancer Claims, Shares Plunge 21%, $2B Market Cap Lost -- Hagens Berman

ImmunityBio Strengthens Balance Sheet with $100 Million of Financing Transactions Including $75 Million of Non-Dilutive Financing to Support Global Expansion and Advancement of Broader Immunotherapy Pipeline

Mar 31, 2026, 7:30 AM EDT - 4 days ago

ImmunityBio Strengthens Balance Sheet with $100 Million of Financing Transactions Including $75 Million of Non-Dilutive Financing to Support Global Expansion and Advancement of Broader Immunotherapy Pipeline

$IBRX Lawsuit: ImmunityBio, Inc. Sued for Securities Fraud; Investors Should Contact Block & Leviton to Possibly Recover Losses

Mar 27, 2026, 12:17 PM EDT - 7 days ago

$IBRX Lawsuit: ImmunityBio, Inc. Sued for Securities Fraud; Investors Should Contact Block & Leviton to Possibly Recover Losses

ImmunityBio Lead Bladder Cancer Drug Trial Clears Power Check

Mar 26, 2026, 10:04 AM EDT - 8 days ago

ImmunityBio Lead Bladder Cancer Drug Trial Clears Power Check

ImmunityBio Confirms Statistical Power in Pivotal Randomized BCG-Naïve NMIBC Trial to Detect Clinically Meaningful Differences Between ANKTIVA® Plus BCG Versus BCG Alone; Supplemental BLA Submission on Track for 2026

Mar 26, 2026, 7:30 AM EDT - 9 days ago

ImmunityBio Confirms Statistical Power in Pivotal Randomized BCG-Naïve NMIBC Trial to Detect Clinically Meaningful Differences Between ANKTIVA® Plus BCG Versus BCG Alone; Supplemental BLA Submission on Track for 2026

ImmunityBio stock price crash: buy the dip or sell the rip?

Mar 24, 2026, 3:25 PM EDT - 10 days ago

ImmunityBio stock price crash: buy the dip or sell the rip?

ImmunityBio Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

Mar 24, 2026, 12:56 PM EDT - 10 days ago

ImmunityBio Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

ImmunityBio Crashes On FDA Warning Over Anktiva Claims

Mar 24, 2026, 11:04 AM EDT - 10 days ago

ImmunityBio Crashes On FDA Warning Over Anktiva Claims

ImmunityBio shares fall on FDA warning letter over cancer therapy claims in ad

Mar 24, 2026, 10:53 AM EDT - 10 days ago

ImmunityBio shares fall on FDA warning letter over cancer therapy claims in ad

ImmunityBio Announces Approval in Macau SAR, China for ANKTIVA® in BCG-Unresponsive NMIBC with CIS ± Papillary Tumors

Mar 20, 2026, 1:08 PM EDT - 14 days ago

ImmunityBio Announces Approval in Macau SAR, China for ANKTIVA® in BCG-Unresponsive NMIBC with CIS ± Papillary Tumors

ImmunityBio's Anktiva Could See More Upside: My Updated Thoughts On Expansion

Mar 17, 2026, 4:39 PM EDT - 17 days ago

ImmunityBio's Anktiva Could See More Upside: My Updated Thoughts On Expansion

ImmunityBio Stock Jumps As New Bladder Cancer Guideline Boosts Anktiva Use

Mar 17, 2026, 1:54 PM EDT - 17 days ago

ImmunityBio Stock Jumps As New Bladder Cancer Guideline Boosts Anktiva Use

ImmunityBio Announces NCCN® Clinical Practice Guidelines in Oncology Have Been Updated to Include ANKTIVA® Plus BCG for Patients With BCG-Unresponsive NMIBC With Papillary-Only Disease

Mar 17, 2026, 7:30 AM EDT - 18 days ago

ImmunityBio Announces NCCN® Clinical Practice Guidelines in Oncology Have Been Updated to Include ANKTIVA® Plus BCG for Patients With BCG-Unresponsive NMIBC With Papillary-Only Disease

Why Is ImmunityBio Stock Soaring On Friday?

Mar 13, 2026, 10:44 AM EDT - 21 days ago

Why Is ImmunityBio Stock Soaring On Friday?

ImmunityBio Achieves Milestone with Large-Scale NK Cell Production and Cryopreservation from Over 60 Healthy and Cancer Donors

Mar 13, 2026, 7:30 AM EDT - 22 days ago

ImmunityBio Achieves Milestone with Large-Scale NK Cell Production and Cryopreservation from Over 60 Healthy and Cancer Donors

ImmunityBio Announces FDA Resubmission For Expanded Use Of Lead Drug

Mar 9, 2026, 11:03 AM EDT - 25 days ago

ImmunityBio Announces FDA Resubmission For Expanded Use Of Lead Drug

ImmunityBio Announces Resubmission of Supplemental BLA to the FDA for ANKTIVA® Plus BCG in BCG-Unresponsive NMIBC with Papillary Disease Following Agency Review of Additional Data

Mar 9, 2026, 7:30 AM EDT - 26 days ago

ImmunityBio Announces Resubmission of Supplemental BLA to the FDA for ANKTIVA® Plus BCG in BCG-Unresponsive NMIBC with Papillary Disease Following Agency Review of Additional Data

ImmunityBio, Inc. (IBRX) Q4 2025 Earnings Call Transcript

Mar 3, 2026, 11:52 PM EST - 4 weeks ago

ImmunityBio, Inc. (IBRX) Q4 2025 Earnings Call Transcript

ImmunityBio to Provide a Business Update and Review Financial Results for FY 2025 on Tuesday, March 3, 2026

Feb 27, 2026, 7:30 AM EST - 5 weeks ago

ImmunityBio to Provide a Business Update and Review Financial Results for FY 2025 on Tuesday, March 3, 2026

ImmunityBio Investors Rally Behind Cancer Trial Milestone

Feb 26, 2026, 8:57 AM EST - 5 weeks ago

ImmunityBio Investors Rally Behind Cancer Trial Milestone

ImmunityBio Completes Enrollment in Pivotal Randomized Trial Evaluating ANKTIVA® Plus BCG Versus BCG Alone in BCG-Naïve Non-Muscle Invasive Bladder Cancer Carcinoma In Situ

Feb 26, 2026, 7:30 AM EST - 5 weeks ago

ImmunityBio Completes Enrollment in Pivotal Randomized Trial Evaluating ANKTIVA® Plus BCG Versus BCG Alone in BCG-Naïve Non-Muscle Invasive Bladder Cancer Carcinoma In Situ

ImmunityBio Supersedes Expectations With Fivefold Revenue Increase

Feb 25, 2026, 1:02 PM EST - 5 weeks ago

ImmunityBio Supersedes Expectations With Fivefold Revenue Increase

ImmunityBio's 471% Stock Rally Could Enter Next Round If Shorts Capitulate

Feb 25, 2026, 9:09 AM EST - 5 weeks ago

ImmunityBio's 471% Stock Rally Could Enter Next Round If Shorts Capitulate

ImmunityBio Founder Dr. Patrick Soon-Shiong to Speak at Milken Institute and Richard Nixon Foundation "Cancer 2035: A Roadmap for the Future" Summit

Feb 23, 2026, 4:15 PM EST - 5 weeks ago

ImmunityBio Founder Dr. Patrick Soon-Shiong to Speak at Milken Institute and Richard Nixon Foundation "Cancer 2035: A Roadmap for the Future" Summit

ImmunityBio Explodes To Near 52-Week High As Bladder Cancer Drug Anktiva Drives Massive 700% Revenue Growth

Feb 23, 2026, 12:34 PM EST - 5 weeks ago

ImmunityBio Explodes To Near 52-Week High As Bladder Cancer Drug Anktiva Drives Massive 700% Revenue Growth

Undercovered Dozen: Agnico Eagle, Lumentum, ImmunityBio And More

Feb 23, 2026, 7:31 AM EST - 5 weeks ago

Undercovered Dozen: Agnico Eagle, Lumentum, ImmunityBio And More

AEM LITE

ImmunityBio Reports 700% Year-Over-Year Revenue Growth, Expanded ANKTIVA® Approvals in Lung Cancer and Global Commercial Partnerships in 33 Countries with Label Expansion Plans Globally

Feb 23, 2026, 7:00 AM EST - 5 weeks ago

ImmunityBio Reports 700% Year-Over-Year Revenue Growth, Expanded ANKTIVA® Approvals in Lung Cancer and Global Commercial Partnerships in 33 Countries with Label Expansion Plans Globally

ImmunityBio Partners with Biopharma and Cigalah Healthcare to Launch ANKTIVA® in Saudi Arabia for Bladder and Lung Cancer Patients

Feb 20, 2026, 8:30 AM EST - 6 weeks ago

ImmunityBio Partners with Biopharma and Cigalah Healthcare to Launch ANKTIVA® in Saudi Arabia for Bladder and Lung Cancer Patients

ImmunityBio Holds Golden Cross As Stock Trades 170% Above 200-Day Average

Feb 19, 2026, 11:37 AM EST - 6 weeks ago

ImmunityBio Holds Golden Cross As Stock Trades 170% Above 200-Day Average

ImmunityBio Expands Access to ANKTIVA® in EU with New Distribution Partnership and Opens Irish Subsidiary to Support European Launch

Feb 19, 2026, 9:00 AM EST - 6 weeks ago

ImmunityBio Expands Access to ANKTIVA® in EU with New Distribution Partnership and Opens Irish Subsidiary to Support European Launch

What's Behind The Jump In ImmunityBio Stock?

Feb 18, 2026, 12:02 PM EST - 6 weeks ago

What's Behind The Jump In ImmunityBio Stock?

ImmunityBio Receives Authorization from the European Commission for ANKTIVA® with BCG for Non-Muscle Invasive Bladder Cancer Carcinoma in Situ, Expanding Global Access to 33 Countries

Feb 18, 2026, 9:00 AM EST - 6 weeks ago

ImmunityBio Receives Authorization from the European Commission for ANKTIVA® with BCG for Non-Muscle Invasive Bladder Cancer Carcinoma in Situ, Expanding Global Access to 33 Countries

ImmunityBio: The Story Surrounding Anktiva So Far

Feb 18, 2026, 5:12 AM EST - 6 weeks ago

ImmunityBio: The Story Surrounding Anktiva So Far

ImmunityBio Reports Productive Regulatory Engagement with Saudi Food and Drug Authority at USA-Saudi Biotech Alliance Meeting Hosted by the Ministry of Investment of Saudi Arabia

Feb 17, 2026, 6:07 AM EST - 6 weeks ago

ImmunityBio Reports Productive Regulatory Engagement with Saudi Food and Drug Authority at USA-Saudi Biotech Alliance Meeting Hosted by the Ministry of Investment of Saudi Arabia

These 10 Stocks Could Be Short Squeeze Targets: Lucid, Kohl's, Avis and More

Feb 2, 2026, 2:08 PM EST - 2 months ago

These 10 Stocks Could Be Short Squeeze Targets: Lucid, Kohl's, Avis and More

CAR KSS LCID CHH HIMS MARA MPT

ImmunityBio Launches Phase 2 Chemotherapy-Free CAR-NK Cell Therapy Trial with ANKTIVA® (ResQ215B) in Indolent Lymphomas

Feb 2, 2026, 7:00 AM EST - 2 months ago

ImmunityBio Launches Phase 2 Chemotherapy-Free CAR-NK Cell Therapy Trial with ANKTIVA® (ResQ215B) in Indolent Lymphomas

ImmunityBio Reports Median Overall Survival Not Yet Reached and Lymphopenia Reversed in Recurrent Glioblastoma Patients Receiving ANKTIVA® Plus CAR-NK, Chemo-Free Therapy

Jan 23, 2026, 7:00 AM EST - 2 months ago

ImmunityBio Reports Median Overall Survival Not Yet Reached and Lymphopenia Reversed in Recurrent Glioblastoma Patients Receiving ANKTIVA® Plus CAR-NK, Chemo-Free Therapy

FDA Talks Set Path For Expanded Use For ImmunityBio's Anktiva In Bladder Cancer

Jan 20, 2026, 1:47 PM EST - 2 months ago

FDA Talks Set Path For Expanded Use For ImmunityBio's Anktiva In Bladder Cancer

Top 3 Health Care Stocks You May Want To Dump In January

Jan 20, 2026, 8:46 AM EST - 2 months ago

Top 3 Health Care Stocks You May Want To Dump In January

ImmunityBio Advances Regulatory Discussions with FDA on Potential Resubmission Path for ANKTIVA® in BCG-Unresponsive Papillary Bladder Cancer

Jan 20, 2026, 4:00 AM EST - 2 months ago

ImmunityBio Advances Regulatory Discussions with FDA on Potential Resubmission Path for ANKTIVA® in BCG-Unresponsive Papillary Bladder Cancer

ImmunityBio, Inc. (IBRX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 16, 2026, 3:45 PM EST - 2 months ago

ImmunityBio, Inc. (IBRX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

ImmunityBio Stock Soars On Cancer Trial Progress, FDA Timeline

Jan 16, 2026, 12:52 PM EST - 2 months ago

ImmunityBio Stock Soars On Cancer Trial Progress, FDA Timeline

ImmunityBio's 700% Revenue Boom Becomes Citadel's Latest I‑Told‑You‑So

Jan 16, 2026, 11:04 AM EST - 2 months ago

ImmunityBio's 700% Revenue Boom Becomes Citadel's Latest I‑Told‑You‑So

Looking For A Short Squeeze? 10 Stocks Ready To Rocket

Jan 16, 2026, 10:41 AM EST - 2 months ago

Looking For A Short Squeeze? 10 Stocks Ready To Rocket

CAR CHH HIMS KSS LCID MARA PCT

LB19
LB19 Apr. 4 at 1:33 PM
$IBRX look at this, look. King Faisal hospital in Saudi, our partnership with them. Sepsis and pneumonia... BioShield etc!
1 · Reply
BeMarsh
BeMarsh Apr. 4 at 1:30 PM
$IBRX
0 · Reply
JayMacy
JayMacy Apr. 4 at 1:27 PM
$IBRX Why did he have to turn his head?
1 · Reply
Rambo309
Rambo309 Apr. 4 at 1:00 PM
$IBRX Hey guys imo this war will not end that soon, bc the more shit happens, the later it will end. I think this coming week will be another test for us shareholder. As long as this war goes on realistically we will have more downs than ups, so we have to stay strong! Just curious when do u guys think this war might end?
2 · Reply
CyberCuba
CyberCuba Apr. 4 at 12:57 PM
$IBRX I agree with thelibsrdum LUKE P HUDOCK post a few minutes ago. Specifically with Type A influenza pneumonia in which severe lymphocytopenia is associated with increased mortality and superinfections such as Aspergillus. Aggressively treating sepsis and influenza patients who are lymphocytopenic is a potential huge market for IBRX Anktiva.
0 · Reply
LB19
LB19 Apr. 4 at 12:54 PM
$IBRX right after posting job for Field Reimbursement Manager who will be responsible for services pertaining to access, coverage, coding, reimbursement, and affordability of IBRX therapeutic products. Then Patrick started all this talk in regards to pneumonia and Sepsis. This also comes after Patrick pounding the table on "Plausible mechanism of action"! It's all being laid out there for us to see, the foundation is being set. All the Dunkirk activity and job postings is not for manufacturing just for the very limited approvals we have. They know what is coming.
0 · Reply
thelibsrdum
thelibsrdum Apr. 4 at 12:34 PM
$IBRX if CAP/sepsis proves to be a successful indication for Anktiva, this is bigger than cancer. This would be a frontline treatment for every pneumonia patient with lightning fast adoption and is in an area BP doesn't even play so all those headwinds disappear. As much as everyone is focused on cancer, this alternative indication could be the moonshot while cancer indication moves along at a much slower
0 · Reply
Regener8
Regener8 Apr. 4 at 11:54 AM
$IBRX $IBRX I wasn’t aware of the Phase 3 registration! (See below) The specific pairing for severe CAP (targeting sepsis-related immunoparalysis/lymphopenia) does not show a preceding standalone Phase 1 in public records or company announcements. The jump to Phase 2 is common when leveraging established safety profiles from related indications, especially for a serious, high-unmet-need condition like severe pneumonia in ICU patients. A separate Phase 3 randomized, blinded, placebo-controlled trial (NCT07492875) for the same combination in severe CAP has also been registered, indicating the program is moving quickly from the small Phase 2 toward confirmatory testing.  This approach aligns with ImmunityBio’s focus on restoring immune competence in lymphopenic or immunosuppressed states, building on data from their cancer and long COVID trials where ANKTIVA has shown lymphocyte-boosting effects. This has the chance to be much bigger than just treating cancer and they are on it! Go Doc!
1 · Reply
NasdaqPulse
NasdaqPulse Apr. 4 at 11:45 AM
The best opportunities don’t show up when everyone agrees — they show up when sentiment is at its worst and volatility is at its highest. 👉Click to view @NasdaqPulse for timely updates amid the volatility. High-beta names are getting punished, but that’s exactly where asymmetric upside lives. Watch these levels, not headlines: • $IBRX • $ACHR • $ORCL • $QBTS • $CRWV The strategy isn’t to chase — it’s to accumulate when weakness persists and liquidity thins out. Volatility = opportunity Fear = entry signal (not exit signal) Patience is the edge here. A bit more downside… and risk/reward starts to skew heavily in your favor. That’s when capital should be deployed — not after the move.
0 · Reply
Mayor_Shark
Mayor_Shark Apr. 4 at 11:34 AM
$IBRX Always so odd to see how hateful bears can be on drugs that are being made to save lives. This Easter I pray for you to have hearts ✝️✌️
0 · Reply
todn
todn Apr. 4 at 10:10 AM
$IBRX Agree!
1 · Reply
todn
todn Apr. 4 at 10:04 AM
$IBRX
0 · Reply
ericmarcellus
ericmarcellus Apr. 4 at 9:06 AM
$ERAS has been crushing it relative to ImmunityBio lately — and the market has shown it. Over the most recent quarter, $IBRX did rally hard, but Erasca actually outpaced it with bigger gains, showing serious momentum in its oncology pipeline and early Phase results driving the move. And if you look at broader biotech returns, ERAS ranks ahead of IBRX on year-to-date performance, with stronger percentage gains vs ImmunityBio’s rally. That doesn’t mean ImmunityBio doesn’t have a story — it does — but in pure recent performance and breakout strength, $ERAS has been the more explosive ticker, and that’s why some traders are calling it the better biotech play right now.
1 · Reply
Stock_n_Roll
Stock_n_Roll Apr. 4 at 9:06 AM
$IBRX The PSS "Stay Tuned" post likely refers to these new Critical Care trials (registered/updated March 25): 1️⃣ Phase 2 (Safety): Start April 15 (estimated) Study Details | NCT07492888 | Nogapendekin Alfa-Inbakicept and iNKT Cells for Critically Ill Adults With Severe Community-Acquired Pneumonia (With or Without Sepsis/ARDS) | https://clinicaltrials.gov/study/NCT07492888 2️⃣ Phase 3 (Pivotal): Start April 15 (estimated) Registrational study for Sepsis. NCT07492875 Study Details | NCT07492875 | Study of Nogapendekin Alfa Inbakicept and iNKT Cells in Critically Ill Adults With Severe Community-Acquired Pneumonia | https://clinicaltrials.gov/study/NCT07492875 Why this is huge: There is currently no effective treatment for Sepsis-induced immune failure. The medical need is massive, and $IBRX is moving straight into Phase 3 to solve it.
0 · Reply
Beroname
Beroname Apr. 4 at 7:29 AM
$IBRX I had a dream. Checked the phone at night and premarket was 10.02$.
1 · Reply
Judykay
Judykay Apr. 4 at 5:32 AM
$IBRX x.com/ChildrensHD/status/2040202697421553735
1 · Reply
Judykay
Judykay Apr. 4 at 5:18 AM
$IBRX I told you I confronted Polly. They now posted the clip. This is RFK Jrs Childrens Health Defense. Dr. Marik was Polly's guest. Here is the link with the chat box. This is a signal to me https://live.childrenshealthdefense.org/chd-tv/shows/good-morning-chd/federal-court-blocks-acip-cancer-and-metabolic-healing-the-peoples-study/
1 · Reply
Pepper214
Pepper214 Apr. 4 at 4:57 AM
$IBRX https://x.com/ActionFixesFear/status/2040082837953716643?s=20 This is Great Story about our Potential
0 · Reply
LB19
LB19 Apr. 4 at 4:46 AM
$IBRX the superhero the world needs!
0 · Reply
Hotresearchsgoldenage
Hotresearchsgoldenage Apr. 4 at 4:46 AM
$IBRX stay invested . The war will end . Oil prices will drop drastically. Trumps Hand picked fed chair will decrease interest rates . Multiple catalysts down the pipe . We could see a bull rally in coming months never seen before. These penny wise but dollar dumb investors play daily movement and most of the time they are wrong . Block the idiots like ibbullchit etc and stay long ! Happy Easter ! Gn
2 · Reply
itco803
itco803 Apr. 4 at 4:34 AM
$IBRX
0 · Reply
Truth_baller
Truth_baller Apr. 4 at 4:19 AM
$IBRX PSA: Expose & Block all shorts here Ain’t shy/timid doing it.
1 · Reply